Open AccessA catalog of numerical centrosome defects in epithelial ovarian cancers
Author(s) -
Morretton JeanPhilippe,
Simon Anthony,
Herbette Aurélie,
Barbazan Jorge,
PérezGonzález Carlos,
Cosson Camille,
Mboup Bassirou,
Latouche Aurélien,
Popova Tatiana,
Kieffer Yann,
Macé AnneSophie,
Gestraud Pierre,
Bataillon Guillaume,
Becette Véronique,
Meseure Didier,
Nicolas André,
Mariani Odette,
VincentSalomon Anne,
Stern MarcHenri,
MechtaGrigoriou Fatima,
Roman Roman Sergio,
Vignjevic Danijela Matic,
Rouzier Roman,
SastreGarau Xavier,
Goundiam Oumou,
Basto Renata
Publication year - 2022
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.202215670
Subject(s) - centrosome , biology , centrosome cycle , ovarian cancer , cancer research , microbiology and biotechnology , cancer , genetics , cell cycle
Centrosome amplification, the presence of more than two centrosomes in a cell is a common feature of most human cancer cell lines. However, little is known about centrosome numbers in human cancers and whether amplification or other numerical aberrations are frequently present. To address this question, we have analyzed a large cohort of primary human epithelial ovarian cancers (EOCs) from 100 patients. We found that rigorous quantitation of centrosome number in tumor samples was extremely challenging due to tumor heterogeneity and extensive tissue disorganization. Interestingly, even if centrosome clusters could be identified, the incidence of centrosome amplification was not comparable to what has been described in cultured cancer cells. Surprisingly, centrosome loss events where a few or many nuclei were not associated with centrosomes were clearly noticed and overall more frequent than centrosome amplification. Our findings highlight the difficulty of characterizing centrosome numbers in human tumors, while revealing a novel paradigm of centrosome number defects in EOCs.